Omada Health (NASDAQ:OMDA) CEO Sells $587,094.48 in Stock

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 25,886 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $22.68, for a total transaction of $587,094.48. Following the transaction, the chief executive officer owned 411,861 shares of the company’s stock, valued at $9,341,007.48. This trade represents a 5.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Omada Health Trading Down 0.1%

Shares of OMDA opened at $22.98 on Thursday. Omada Health, Inc. has a 12-month low of $10.28 and a 12-month high of $26.92. The stock has a market cap of $1.37 billion and a P/E ratio of -85.11. The company has a 50-day moving average of $17.83 and a two-hundred day moving average of $15.27.

Omada Health (NASDAQ:OMDA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.03. Omada Health had a negative net margin of 2.22% and a negative return on equity of 1.82%. The business had revenue of $78.05 million for the quarter. As a group, analysts forecast that Omada Health, Inc. will post -0.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC acquired a new stake in shares of Omada Health during the second quarter worth $637,000. Walleye Capital LLC acquired a new position in Omada Health in the second quarter valued at $458,000. Ilex Capital Partners UK LLP acquired a new position in Omada Health in the second quarter valued at $201,000. Soros Fund Management LLC purchased a new position in Omada Health during the second quarter worth about $640,000. Finally, Raymond James Financial Inc. purchased a new position in Omada Health during the second quarter worth about $32,000.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Citigroup reissued an “outperform” rating on shares of Omada Health in a research report on Friday, May 8th. Wall Street Zen upgraded Omada Health from a “hold” rating to a “buy” rating in a research report on Saturday, June 27th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Omada Health in a research note on Friday, May 8th. Canaccord Genuity Group set a $24.00 target price on shares of Omada Health in a research note on Friday, May 8th. Finally, Weiss Ratings upgraded shares of Omada Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 26th. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Omada Health currently has a consensus rating of “Moderate Buy” and an average price target of $22.91.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.